10-Q: SS Innovations International Reports Strong Revenue Growth in First Quarter, Faces Auditor Change

SS Innovations International reported a significant increase in revenue for the first quarter of 2024, but is filing its quarterly report without auditor review due to the SEC barring its previous auditor.

Summary

• SS Innovations International, Inc. reported a net loss of $2,798,448 for the quarter ended March 31, 2024, compared to a net loss of $2,992,362 for the same period in 2023.
• The company's revenue increased significantly to $6,851,058 for the quarter, up from $1,511,379 in the first quarter of 2023, driven by the sale of 8 surgical robotic systems.
• Operating expenses totaled $5,695,897, which included $1,937,202 in stock compensation expense and $2,611,019 in selling, general, and administrative expenses.
• The company's total assets were $31,045,225, and total liabilities were $17,509,627 as of March 31, 2024.
• SS Innovations had a total of 32 surgical robotic systems installed as of the end of the first quarter of 2024, including systems sold, installed on a pay-per-use basis, and for clinical evaluation.
• The company raised $2.45 million through convertible promissory notes in February 2024 and an additional $2 million in April 2024.
• The company is currently seeking a new independent registered public accounting firm after its previous auditor was barred by the SEC.

Sentiment

Score: 6

Explanation: The document shows strong revenue growth and expansion, but is tempered by the net loss, auditor issues, and concerns about internal controls and going concern. The sentiment is cautiously optimistic.

Positives

• The company experienced a substantial increase in revenue, driven by higher system sales.
• The company has expanded its installed base of surgical robotic systems to 32.
• The company has successfully raised additional capital through convertible promissory notes.
• The net loss decreased compared to the same quarter last year.

Negatives

• The company is reporting a net loss for the quarter.
• The company's previous auditor was barred by the SEC, requiring the company to find a new auditor.
• The company's disclosure controls and procedures were deemed not fully effective due to lack of written documentation and complete segregation of duties.
• The company has a significant accumulated deficit of $38,127,694 as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's disclosure controls and procedures were not fully effective, which could lead to errors in financial reporting.
• The company is currently operating without a reviewed audit, which could impact investor confidence.
• The company faces risks related to scaling up manufacturing, conducting clinical trials, and meeting regulatory requirements.

Future Outlook

The company plans to expand its manufacturing capacity, conduct global clinical trials, and establish regional marketing offices. They are actively seeking long-term funding through equity or loans to support these initiatives. The company is also working to engage a new independent registered public accounting firm and amend the report as soon as practicable.

Management Comments

• Management believes that it will be successful in its capital formation and planned expansion of its operating activities.
• Management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.

Industry Context

The company is operating in the growing surgical robotics market, aiming to make advanced surgical technologies more accessible and affordable, particularly in underserved regions. The company's focus on cost-effective solutions aligns with the trend of increasing demand for affordable healthcare technologies.

Comparison to Industry Standards

• The company's revenue growth is significant compared to the previous year, indicating strong market demand for its surgical robotic systems.
• The company's focus on expanding its installed base is consistent with the strategies of other medical device companies in the robotics sector.
• The company's net loss is not unusual for a growth-stage company in the medical device industry, which often requires significant upfront investment in research, development, and sales.
• The company's need to find a new auditor is a significant issue that could impact investor confidence and is not typical for established companies in the industry. Companies like Intuitive Surgical and Stryker have long-standing relationships with their auditors.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings currently pending or threatened against the company other than those previously reported.

Related Party Transactions

• The company has $1,409,555 in amounts due from related parties as of March 31, 2024.
• The company sold $1,000,000 in convertible promissory notes to Sushruta Pvt Ltd., a related party, in February 2024.
• The company raised $2 million from Sushruta Pvt Ltd. in April 2024.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and the need to raise additional capital.
• Employees may be impacted by the company's efforts to scale up operations and improve internal controls.
• Customers may benefit from the company's expansion and increased access to its surgical robotic systems.
• Creditors may be impacted by the company's debt financing activities.

Next Steps

• The company needs to engage a new independent registered public accounting firm.
• The company will amend the quarterly report once the auditor review is complete.
• The company will continue to seek additional funding to support its growth plans.
• The company will work to improve its internal controls and procedures.

Key Dates

Keywords

surgical robotics, medical devices, revenue growth, financial results, auditor change, convertible notes, capital raise, SSi Mantra, healthcare technology